Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

Completed · Phase 1

Conditions studied: Refractory Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia

In brief

This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy (CY/FLU) in subjects with refractory or relapsed acute myelogenous leukemia (AML). FATE-NK100 is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype. The NK cell product is comprised of peripheral blood (PB) leukocytes sourced from a related donor (HLA-haploidentical or better but not fully HLA-matched) that is seropositive for cytomegalovirus (CMV+), and enriched for adaptive NK cells by depletion of CD3+ (T-lymphocytes) and CD19+ (B-lymphocytes) cells followed by ex-vivo culture expansion.

Key facts

Study ID

NCT03081780

Run by

Masonic Cancer Center, University of Minnesota

People needed

6

Starts

2017-04-27

Expected to finish

2020-12-01

Last updated by the study team

2021-03-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 but ≤ 70 years of age
• Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:
• Primary induction failure:
• * De Novo AML: no CR after 2, 3 or 4 induction attempts with high dose chemotherapy
• Secondary AML (from MDS or treatment related): no CR after 1, 2 or 3 cycles of high dose chemotherapy
• Relapsed:
• Not in CR after 1 or 2 cycles of standard re-induction therapy
• Relapse diagnosed at the time of the 6 months post-HCT standard of care follow-up or later (i.e. based on bone marrow biopsy performed Day +170 or later) and without evidence of graft versus host disease (GVHD)
• For patients > 60 years of age, the minimum of 1 cycle of standard chemotherapy is not required.
• Available HLA-matched or better but not fully HLA-matched (2/4 or 3/4 antigens) related donor (aged 18 to 75 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus who is CMV seropositive.
• Karnofsky Performance Status ≥ 60%
• Adequate organ function within 14 days of study registration (28 days for pulmonary and cardiac) defined as:
• Creatinine: Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73m\^2 per current institutional calculation formula
• Hepatic: AST and ALT ≤ 3 x upper limit of institutional normal
• Pulmonary Function: oxygen saturation ≥ 90% on room air; PFT's required only if symptomatic or prior known impairment - must have pulmonary function >50% corrected DLCO and FEV1
• Cardiac Function: LVEF ≥ 40% by echocardiography or MUGA
• No symptomatic active conduction system abnormalities
• Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to FATE-NK100 cell infusion (excluding preparative regimen premedications)
• Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
• Voluntary written consent prior to the performance of any research related procedures
• Arm Specific Inclusion Criteria
• High-Risk aGVHD (ARM 1):
• Pediatric or adult (ages 0-76 years) HCT recipients with high-risk acute GVHD, as determined either by the refined MN acute GVHD risk score [28]: http://z.umn.edu/MNAcuteGVHDRiskScore OR high risk on the basis of blood biomarkers (Ann Arbor Score 3) [31]. Patients in this arm must start treatment within the first 7 days after onset of high-risk aGVHD.
• or
• Steroid- Dependent aGVHD (ARM 2A):

You may not qualify if…

• Myocardial Infraction (MI) within the previous 6 months
• Acute leukemias of ambiguous lineage
• Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
• History of or known active CNS involvement with AML
• Active autoimmune disease requiring systemic immunosuppressive therapy
• History of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)
• New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
• Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
• Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)

Where it is running

• University of Minnesota, Masonic Cancer Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.